PMC:7696151 / 1827-2076 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"53","span":{"begin":45,"end":73},"obj":"Disease"},{"id":"58","span":{"begin":107,"end":114},"obj":"Chemical"},{"id":"61","span":{"begin":123,"end":130},"obj":"Disease"}],"attributes":[{"id":"A53","pred":"tao:has_database_id","subj":"53","obj":"MESH:D008180"},{"id":"A58","pred":"tao:has_database_id","subj":"58","obj":"MESH:D011803"},{"id":"A61","pred":"tao:has_database_id","subj":"61","obj":"MESH:D008288"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"n began to be also used for the treatment of systemic lupus erythematosus [1,2,3].\nThe increasing need for quinine, due to malaria diffusion, led the pharmaceutical industry to the creation of a synthetic molecule. In 1934 Johann (Hans) Andersag and"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T3","span":{"begin":45,"end":73},"obj":"Phenotype"}],"attributes":[{"id":"A3","pred":"hp_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/HP_0002725"}],"text":"n began to be also used for the treatment of systemic lupus erythematosus [1,2,3].\nThe increasing need for quinine, due to malaria diffusion, led the pharmaceutical industry to the creation of a synthetic molecule. In 1934 Johann (Hans) Andersag and"}

{"project":"LitCovid-sentences","denotations":[{"id":"T18","span":{"begin":83,"end":214},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"n began to be also used for the treatment of systemic lupus erythematosus [1,2,3].\nThe increasing need for quinine, due to malaria diffusion, led the pharmaceutical industry to the creation of a synthetic molecule. In 1934 Johann (Hans) Andersag and"}